Chinese Regulators Provide Fast-track Review Status For Lotus On Modified Version Of AstraZeneca's Bambec
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Lotus Pharmaceuticals, a Beijing-based drug maker and distributor of Western medicines, announced April 29 that the company had received clinical trial approval for its innovative anti-asthma drug R-Bambuterol Hydrochloride (laevo-bambuterol) from China's State FDA
You may also be interested in...
Asia Respiratory Group Launches Online Resource For Doctors To Treat Growing Asthma
SINGAPORE - The General Practitioner Asia Pacific Respiratory Board has launched a new website for doctors across the region to improve primary care in terms of respiratory health
Asia Respiratory Group Launches Online Resource For Doctors To Treat Growing Asthma
SINGAPORE - The General Practitioner Asia Pacific Respiratory Board has launched a new website for doctors across the region to improve primary care in terms of respiratory health
China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference
SHANGHAI - China's State FDA issued regulations on a special approval procedure to accelerate the approval process for new drug applications, effective Jan. 7